Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.nebraska.edu

Clinical Trials

Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: fluorouracil
Drug: gemcitabine hydrochloride
Drug: leucovorin calcium
Drug: oxaliplatin
Procedure: adjuvant therapy
Procedure: conventional surgery
Procedure: neoadjuvant therapy
Radiation: radiation therapy

First Posted Date: 2004-08-05

Last Posted Date: 2023-09-29

Lead Sponsor: University of Nebraska

Target Recruit Count: 29

Registration Number: NCT00089024

Locations: 🇺🇸
Eppley Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, United States

Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Neutropenia
Lymphoma

Interventions: Biological: filgrastim
Biological: pegfilgrastim
Drug: cisplatin
Drug: cytarabine
Drug: etoposide
Drug: methylprednisolone

First Posted Date: 2004-06-25

Last Posted Date: 2023-12-27

Lead Sponsor: University of Nebraska

Target Recruit Count: 60

Registration Number: NCT00004192

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-06-25

Last Posted Date: 2023-09-07

Lead Sponsor: University of Nebraska

Registration Number: NCT00004197

Locations: 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2004-05-25

Last Posted Date: 2023-12-27

Lead Sponsor: University of Nebraska

Registration Number: NCT00004112

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-05-21

Last Posted Date: 2023-12-27

Lead Sponsor: University of Nebraska

Registration Number: NCT00004198

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: autologous dendritic cell-adenovirus p53 vaccine

First Posted Date: 2004-05-19

Last Posted Date: 2023-09-22

Lead Sponsor: University of Nebraska

Target Recruit Count: 24

Registration Number: NCT00082641

Locations: 🇺🇸
Eppley Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, United States

Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: autologous bone marrow transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2004-04-08

Last Posted Date: 2023-10-06

Lead Sponsor: University of Nebraska

Target Recruit Count: 68

Registration Number: NCT00080886

Locations: 🇺🇸
University of Nebraska Medical Center, Eppley Cancer Center, Omaha, Nebraska, United States

Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2004-02-12

Last Posted Date: 2023-09-01

Lead Sponsor: University of Nebraska

Target Recruit Count: 44

Registration Number: NCT00007852

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 3

Terminated

Conditions: Lymphoma

First Posted Date: 2003-12-16

Last Posted Date: 2018-01-17

Lead Sponsor: University of Nebraska

Target Recruit Count: 31

Registration Number: NCT00004874

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-09-18

Last Posted Date: 2013-07-10

Lead Sponsor: University of Nebraska

Target Recruit Count: 30

Registration Number: NCT00002638

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy